Successful Treatment with Etanercept of a Patient with Psoriatic Arthritis after Adalimumab-Related Hepatotoxicity

Inhibitors of Tumor Necrosis Factor (TNF) alpha (infliximab, etanercept, adalimumab) are nowadays widely used for the treatment of rheumatoid arthritis (RA), psoriatic arthritis (PsA) and ankylosing spondylitis (AS), not responding to conventional therapies. Anti-TNF alpha drugs have demonstrated gr...

Full description

Saved in:
Bibliographic Details
Published in:International journal of immunopathology and pharmacology 2009-04, Vol.22 (2), p.547-549
Main Authors: Massarotti, M., Marasini, B.
Format: Article
Language:English
Subjects:
Adalimumab
Antibodies, Monoclonal - adverse effects
Antibodies, Monoclonal, Humanized
Arthritis, Psoriatic - drug therapy
Arthritis, Psoriatic - immunology
Chemical and Drug Induced Liver Injury
Etanercept
Humans
Immunoglobulin G - therapeutic use
Immunosuppressive Agents - adverse effects
Immunosuppressive Agents - therapeutic use
Liver Diseases - diagnosis
Liver Function Tests
Male
Middle Aged
Receptors, Tumor Necrosis Factor - therapeutic use
Treatment Outcome
Tumor Necrosis Factor-alpha - antagonists & inhibitors
Citations: Items that this one cites
Items that cite this one
Online Access:Request full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Inhibitors of Tumor Necrosis Factor (TNF) alpha (infliximab, etanercept, adalimumab) are nowadays widely used for the treatment of rheumatoid arthritis (RA), psoriatic arthritis (PsA) and ankylosing spondylitis (AS), not responding to conventional therapies. Anti-TNF alpha drugs have demonstrated great efficacy in slowing the disease, however, to date, concern still remains regarding acute and long-term toxicity related to TNF block. Increase in liver tests may be observed during treatment with anti-TNF agents, more often related to concomitant drugs (i.e. NSAIDS, methotrexate) or to reactivation of chronic HBV or HCV infections. However, liver damage directly induced by the drug has been described in patients treated with infliximab or adalimumab. To our knowledge, no cases of liver injury closely related to etanercept have been reported so far. We report the case of a patient with PsA who presented liver dysfunction during adalimumab, subsequently successfully treated with etanercept.
ISSN:0394-6320
2058-7384
DOI:10.1177/039463200902200234